At in-cosmetics Asia 2026 in Bangkok, Thailand, BASF Care Creations launched Lincare, a flaxseed-derived bio-active ingredient designed to accelerate skin barrier recovery following dermatological procedures. Clinical testing by the chemical manufacturer demonstrates that a 1 per cent formulation of Lincare accelerates skin barrier repair by 21 per cent after non-ablative fractional laser treatment, alongside measurable increases in long-term skin density.
The launch targets the market for dermo-cosmetics formulated for use after light- and energy-based clinical procedures.
Polysaccharides and Extracellular Remodelling
Lincare is processed from flaxseed hull oligosaccharides, utilising specific carbohydrate chains to stimulate epidermal regeneration. The active targets the structural mechanisms of skin recovery, promoting both epidermal barrier restoration and the synthesis of structural proteins required for extracellular matrix remodelling.
When skin undergoes non-ablative fractional laser treatment, microscopic zones of thermal injury are created to stimulate collagen production without removing the surface skin layer. While less invasive than ablative procedures, non-ablative lasers leave the skin barrier temporarily compromised, leading to elevated transepidermal water loss and inflammation. BASF stated that Lincare was formulated specifically to address this window of vulnerability, accelerating the natural repair cycle while reinforcing structural skin integrity over time.
By focusing on fractional laser recovery, BASF is positioning the active for professional skin care products and clinical post-treatment lines. The 21 per cent recovery acceleration metric provides finished product developers with a concrete clinical baseline for post-procedure efficacy claims.
A Direct Challenge to Synthetic Repair Actives
The move highlights how ingredient suppliers are shifting from broad soothing claims to clinical validation for compromised skin.
In this space, BASF Care Creations competes directly with speciality ingredient producers such as Evonik, Croda, and Givaudan, all of which have built out portfolios focused on skin barrier repair and recovery. While synthetic peptides and ceramide precursors have historically dominated post-procedure formulations, Lincare’s botanical extraction route offers brand partners an oligosaccharide-based alternative with distinct claims around tissue remodelling.
As consumer adoption of light- and energy-based dermatological therapies grows globally, dermo-cosmetic brands are seeking ingredients that bridge the gap between clinical intervention and at-home maintenance. Actives that demonstrate measurable reductions in barrier recovery time allow brands to market directly to consumers seeking to optimise the results of clinical treatments.
Pricing and Regulatory Unknowns
BASF has not yet released complete technical specifications for finished product developers. Key formulation parameters—including pH stability ranges, heat tolerance during processing, and compatibility with standard emulsion systems—remain undisclosed.
BASF has not yet disclosed processing stability metrics, regional regulatory approval timelines or pricing tiers for the active.
The pace at which dermo-cosmetic houses incorporate Lincare into clinical post-treatment lines will test whether plant-derived oligosaccharides can displace synthetic peptides and lipid complexes in post-procedure care.